Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells

Ovarian cancer is the most lethal type of gynecological cancer. Due to its high heterogeneity and complicated pathological mechanisms, the 5-year survival rate of patients with ovarian cancer is <40%. Tumor cytoreductive surgery and systemic chemotherapy of platinum combined with paclitaxel are c...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Jianwen, Wang, Zehua, Fu, Jiayu, A., Jisaihan, Ohno, Yuko, Xu, Congjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290430/
https://www.ncbi.nlm.nih.gov/pubmed/34335884
http://dx.doi.org/10.3892/etm.2021.10367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290430/
https://www.ncbi.nlm.nih.gov/pubmed/34335884
http://dx.doi.org/10.3892/etm.2021.10367

Ejemplares similares